Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Can-Fite BioPharma Ltd. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 9 | 8 | −1 |
| Shares | 243.8K | 477.6K | +233.8K (+95.9%) |
| Value | $536.4K | $1.06M | +$523.8K (+97.7%) |
New holders (2)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 14,171 | $31.5K | 0.00% |
| UBS Group AG | 2,172 | $4.82K | 0.00% |
Sold out (3)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Schechter Investment Advisors, LLC | 20,077 | $44.2K |
| Stone House Investment Management, LLC | 470 | $1.03K |
| TD Waterhouse Canada Inc. | 20 | $54 |